Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.533
Abstract: 533Background: Sorafenib or lenvatinib are the current frontline options for advanced HCC. Multiple biologic agents including multi-Tyrosine Kinase Inhibitors (TKI) cabozantinib & regorafenib have ... read more here.
Keywords: biologics second; immunotherapy versus; therapy advanced; versus biologics ... See more keywords
"Security dilemma": active immunotherapy before versus after radiation therapy alone or chemo-radiotherapy for newly diagnosed glioblastoma.
Sign Up to like & getrecommendations! Published in 2022 at "Folia medica"
DOI: 10.3897/folmed.64.e62981
Abstract: Management of glioblastoma should be aggressive and personalised to increase the quality of life. Many new therapies, such as active immunotherapy, increase the overall survival, yet they result in complications which render the search for… read more here.
Keywords: versus radiation; security dilemma; glioblastoma; dilemma active ... See more keywords